Diosmin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Diosmin: From Venous Insufficiency to Amenorrhea
One-Sentence Summary
Diosmin is a flavonoid-based venotonic and vascular protectant, widely used for the management of chronic venous insufficiency and haemorrhoids. The TxGNN model predicts it may be effective for Amenorrhea, however there are currently no clinical trials and no publications supporting this specific repurposing direction. The mechanistic link between Diosmin’s vascular activity and the hormonal pathophysiology of amenorrhea is considered extremely weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic venous insufficiency, haemorrhoids (venotonic/vascular protectant) |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 — Model prediction only, no actual studies |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacological literature, Diosmin is a semi-synthetic flavonoid glycoside derived from hesperidin. It acts primarily as a venotonic agent — enhancing venous wall tone, reducing venous distensibility, and decreasing capillary permeability. It also possesses anti-inflammatory and lymphatonic properties. Its established clinical use centres on chronic venous disease (leg heaviness, oedema, varicose veins) and acute haemorrhoidal episodes.
The predicted new indication — amenorrhea — is fundamentally a disorder of the hypothalamic-pituitary-ovarian (HPO) axis, involving disruptions in gonadotropin-releasing hormone, FSH/LH signalling, or end-organ (ovarian/uterine) responsiveness. The pathophysiological basis of amenorrhea is hormonal, not vascular, and the molecular targets of Diosmin (venous smooth muscle tone, capillary permeability mediators) have no established overlap with HPO axis regulation.
While some flavonoids are reported to exhibit weak phytoestrogenic activity through interaction with oestrogen receptors, there is no published evidence that Diosmin specifically possesses clinically meaningful oestrogenic or progestogenic effects. The high TxGNN prediction score (99.42%) likely reflects structural proximity between drug and disease nodes within the knowledge graph — a topological artefact rather than a genuine biological causal relationship. This interpretation is consistent with the complete absence of any clinical or preclinical evidence linking Diosmin to amenorrhea.
Clinical Trial Evidence
Currently no related clinical trials registered for the Diosmin–Amenorrhea combination on ClinicalTrials.gov or ICTRP.
Literature Evidence
Currently no related literature available on PubMed for the Diosmin–Amenorrhea combination.
Malaysia Market Information
There are 20 registered products containing Diosmin with the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. However, detailed registration data (authorization numbers, product names, dosage forms, and approved indications) was not available in the current evidence pack.
| Item | Content |
|---|---|
| Total Registrations | 20 |
| Product Details | Pending retrieval from NPRA database |
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug–drug interaction data were not available in the current evidence pack. No drug interactions were identified in the DrugBank query.
Note: Safety data gaps are classified as Blocking (DG001) — a full safety assessment cannot proceed until package insert warnings and contraindications are retrieved from the NPRA or equivalent regulatory source.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link between Diosmin (a venotonic/vascular protectant) and amenorrhea (a hormonal/endocrine disorder) is extremely weak, with no shared molecular targets identified. Despite a high TxGNN prediction score, there is a complete absence of supporting evidence — zero clinical trials, zero publications, and zero preclinical studies. The high score likely reflects knowledge graph structural proximity rather than biological plausibility.
To proceed, the following is needed:
- Mechanism of action (MOA) data to evaluate any potential hormonal or endocrine activity of Diosmin
- Package insert safety data (warnings, contraindications) from NPRA — currently a blocking data gap
- Preclinical evidence of any oestrogenic, progestogenic, or HPO-axis modulating effects of Diosmin or related flavonoids
- At minimum one observational or mechanistic study suggesting biological plausibility before advancing from Hold status
- Detailed NPRA registration records (authorization numbers, product names, approved indications)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.